Canada markets open in 5 hours 17 minutes

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
38.49+1.58 (+4.28%)
At close: 04:00PM EST
38.78 +0.29 (+0.75%)
After hours: 07:59PM EST
Full screen
Loading interactive chart...
  • GlobeNewswire

    Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease

    Outside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately Year-End 2022, Pending Completion of Study Report by Outside Biostatisticians. AUSTIN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the completion of drug administration in an open-label study of simufilam for Alzhe

  • GlobeNewswire

    Cassava Sciences Announces Closing of $50 Million Registered Direct Offering

    AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 1,666,667 shares of its common stock, at a purchase price per share of $30, for gross proceeds of approximately $50 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. JonesTrading

  • GlobeNewswire

    Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock

    AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has entered into a definitive agreement with several healthcare-focused and other institutional investors for the purchase of 1,666,667 shares of its common stock, at a purchase price of $30 per share, for gross proceeds of approximately $50 million, in a registered direct offer